1 / 21

The Best Pharmaceuticals for Children Act

The Best Pharmaceuticals for Children Act. Anne Zajicek, M.D., Pharm.D. Pediatric Medical Officer National Institute of Child Health and Human Development National Institutes of Health. Best Pharmaceuticals for Children Act.

nhung
Download Presentation

The Best Pharmaceuticals for Children Act

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. The Best Pharmaceuticals for Children Act Anne Zajicek, M.D., Pharm.D. Pediatric Medical Officer National Institute of Child Health and Human Development National Institutes of Health

  2. Best Pharmaceuticals for Children Act • Enacted January 2002, exclusivity provision will sunset October 2007 • Continues exclusivity provision of FDAMA • Purpose: pediatric labeling

  3. Pediatric Labeling • Pre-approval: Pediatric Research Equity Act • On-patent: • Best Pharmaceuticals for Children Act which continues the exclusivity provisions of FDAMA • Studies supported by the Foundation for the NIH • Off-patent: Best Pharmaceuticals for Children Act

  4. Best Pharmaceuticals for Children Act • In pediatric oncology • prioritize new drugs for study • assure timely access to new treatments • develop pre-clinical models of pediatric cancers

  5. Master List of all Off-Patent Drugs which lack adequate pediatric labeling N=200 • Consider for prioritizing: • Availability of S/E data • Are additional data needed? • Will new studies produce • health benefits? • Reformulation? Consultation with experts in pediatric practice and research Develop, prioritize, publish an Annual List N=5-15

  6. Priority List • Developed by NIH • In consultation with • Institutes and Centers of the National Institutes of Health • Federal Agencies • Food and Drug Administration • Centers for Disease Control and Prevention • Pediatric subspecialists and subspecialty groups • Advocacy groups

  7. Azithromycin Baclofen* Bumetanide Dobutamine Dopamine Furosemide Heparin Lithium Lorazepam Rifampin Sodium nitroprusside Spironolactone Drugs on the Priority List: January 2003FR 68: 13; Jan 21, 2003

  8. Ampicillin/sulbactam Diazoxide Isoflurane Lindane Meropenem Metoclopramide* Piperacillin/ tazobactam Promethazine Drugs on the Priority List: August 2003FR 68: 156; Aug 13, 2003

  9. Drugs on the Priority List: February 2004FR 69:30; February 13, 2004 • Ampicillin • Ketamine • Vincristine • Actinomycin-D • Metolazone

  10. Drugs on the Priority List: January 2005FR 70:17; January 27, 2005 • Ivermectin • Hydrocortisone valerate • Hydrochlorothiazide • Ethambutol • Griseofulvin • Methadone • Hydroxychloroquine • Sevelamer* • Morphine*

  11. Drugs on the Priority List: April 2006FR 70:79; April 25, 2006 • ADHD: methylphenidate • Hypertension: diuretics • Parasitic Diseases: albendazole, mebendazole • Influenza: amantidine, rimantidine • Cancer: methotrexate, daunomycin • Poisonings: pralidoxime • Sickle Cell Anemia: hydroxyurea

  12. Drugs on the Priority List:March 2007FR 72: 14588; March 28, 2007 • Infectious Diseases: Methicillin-resistant Staph aureus infection • Clindamycin, tetracyclines, trimethoprim-sulfamethoxazole • Hypertension: clinical trial designs • Neonatal Research: clinical trial designs • Cancer: Neuroblastoma • 13-cis retinoic acid • Asthma: clinical trial designs in young children

  13. FDA Issues a Written Request:On-Patent Accept WR sent to Holder of NDA From Priority List FDA issues Written Request (WR) Referred to FNIH for funding Decline

  14. FDA Issues a Written Request: Off-Patent Accept WR sent to Holders of NDA/ aNDA From Priority List FDA issues Written Request (WR) Referred to NIH for contract Decline

  15. Contracting Process WR referred to NIH RFC* FedBizOpps RFP* Proposals peer-reviewed *RFC=request for contract *RFP=request for proposal Contract(s) awarded

  16. Results So Far…

  17. Studies On-Going under BPCA • Lorazepam: Clinical studies for treatment of status epilepticus • Study 1: PK • Study 2: Efficacy, safety study comparing lorazepam to diazepam • Lorazepam: Clinical studies of sedation of children on ventilators in an intensive care unit • Nitroprusside: Clinical studies to reduce blood pressure during surgery to reduce blood loss • Lithium: Clinical studies to define treatment of mania in children with bipolar disorder • Baclofen: Clinical studies of oral baclofen to treat spasticity, most commonly from cerebral palsy

  18. Studies On-Going • Ketamine - Preclinical studies to evaluate the scientific and safety concerns about the use as an anesthetic in children • Hydroxyurea- Clinical studies to improve treatment of children with sickle cell disease (NHLBI) • Methylphenidate – Preclinical and clinical evaluation of pharmacokinetics and safety to understand reports of cytogenetic toxicity (NIEHS) • Morphine – preclinical basic science evaluations of the developmental expression of opioid receptors to better understand management of pain in children of different developmental stages and safety issues in treating pain in neonates

  19. Studies On-Going under BPCA • Vincristine: Studies to evaluate neurotoxicity, PK in children (NCI-COG) • Actinomycin-D: Studies to evaluate hepatotoxicity/ VOD, PK in children (NCI-COG) • Methotrexate: Clinical studies to evaluate neurocognitive outcomes of pediatric patients with high risk acute lymphoblastic leukemia (NCI-COG) • Daunomycin: Pharmacokinetics, safety, efficacy of daunomycin to treat childhood cancers and relationship to body weight (NCI-COG)

  20. Vincristine and Actinomycin-D • Retrospective chart review of • Demographics • Treatment history • Toxicity • Neurotoxicity • Veno-occlusive disease • Line-clearing method • Pharmacokinetic modeling • Prospective PK study

  21. Summary • Partnership with FDA • NIH responsible for • prioritizing list of drugs for study • sponsoring clinical studies in children that will improve pediatric therapeutics

More Related